COVID-19 PFIZER Vaccination Consent for 12yo through Adults Gray label (12yo and older)

Last name:		First Name:	Middle Initial:		
Home Zip C	ode:	: Date of birth:	Age:		
COVID-19 vaccination	1.	Are you sick today? (minor illness is not a contraindication to	vaccination)	□ Yes	□No
screening questions:	2.	Do you have a life-threatening allergy to any vaccine or any va NOT VACCINATE. Speak with your provider.	ccine components? If yes, DO	□ Yes	□No
	3.	Are you pregnant or breastfeeding? (Discussion of risks and benefits with your PCP is recommended prior to vaccination. This is not a contraindication.)			
	4.	Are you immunosuppressed due to health condition or treatm	ent? (mark on reverse)	☐ Yes	□No
	5.	I am □Unvaccinated against COVIDGive Updated 2023-2024 COV	ID vaccine		
	6.	I am □Vaccinated against COVID, but it has been at least 2 mont Give updated 2023-2024 vaccine	hs since any COVID vaccine —		
INFORMED	o co	ONSENT:			
I, (print nan vaccination	_	, hereby	acknowledge and assume the	risk of CO	VID-19
I understand t	he CC	OVID-19 Pfizer 2023-2024 Vaccination has received FDA Authorization for opportunity to review the patient fact sheet for this vaccine.	for prevention of COVID-19 in person	s 12 years o	ld or
		at there is limited information known about the safety and	d efficacy of using the COVID-1	.9 vaccine	
		expected side effects may occur. Known possible side effe			
face Imn Pair Swo	e, or mune n/sw ollen	reactions: low blood pressure, changes in heartbeat, shor throat, rash, nausea, vomiting, sweating, or shivering, pose e system reaction: fever, muscle/joint aching, myalgia, heavelling/redness at injection site a lymph nodes, particularly after a booster dose e (fainting) may occur with administration of injectable valuely: inflammation of the heart muscle or the tissues surro	ssible during or after infusion adache, fatigue, nausea/vomiticccines, especially among adole	ing	ne lips,
		stand the COVID-19 vaccine may cause additional risks, so	•		n at
opportunity YES, I cor the vaccir	/ to r nsen ne d	dition to the risks described above, as well as those risks for review the fact sheet on this medication. (Continue to rev int to have the COVID-19 vaccine given to me/ my ch loes not preclude me/my child from wearing a mask omply with Minnesota Department of Health regula	erse.) nild (circle). I understand t when recommended and I	hat recei	
Pat	ient/	Representative Signature & Relationship to patient	Date		
GRAY	CA	AP 12 AND OLDER 0.3ML			
Date adminis	stere	d/info given:/	Date of vaccine info sheet: 9/	11/2023	
Lot #:		Mfg	CPT Code:		

Date administered/info given:/	Date of vaccine info sheet: 9/11/2023	
Lot #:	Mfg:	CPT Code:
	Pfizer Bivalent COVID-19	
Route/Dose:	IM Site:	Name and title of vaccine administrator:
0.3ml IM GRAY cap (12 +)	R delt L delt	

COVID-19 PFIZER Vaccination Consent for 12yo through Adults Gray label (12yo and older)

ELIGIBILITY FOR IMMUNOCOMPROMISED DOSE OF COVID PFIZER VACCINE
Currently receiving treatment for cancer
Have had an organ transplant and are on immunosuppression therapy
Have had a blood stem cell transplant or CAR-T cell transplant AND
are within 2 years of transplant or
are on immunosuppression therapy
Currently being treated with immunosuppressive medications such as
high dose corticosteroids (>20 mg prednisone or equivalent/day)
alkylating agents, antimetabolites, TNF blockers, severely immunosuppressive cancer chemotherapeutic agents, transplant related immunosuppressive drugs
other biologic agents that are immunosuppressive or immunododulatory*
Have advanced or untreated HIV infection
Have a moderate or severe PRIMARY immunodeficiency (e.g. DiGeorge syndrome, Wiskott-Aldrich syndrome

9/13/2023 jp